{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:51:03Z","timestamp":1765547463747,"version":"build-2065373602"},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Was ist neu?<\/jats:title>\n                  <jats:p>Neu, in Europa verf\u00fcgbare Immuntherapien zur Behandlung solider Tumore, sind prim\u00e4r auf monoklonalen Antik\u00f6rpern basierende Medikamente. Dazu z\u00e4hlen das Immunkonjugat Mirvetuximab-Soravtansin f\u00fcr die Therapie des Folatrezeptor-alpha-positiven Ovarialkarzinoms, der monoklonale Antik\u00f6rper Zolbetuximab f\u00fcr das Claudin-18.2-positive Adenokarzinom des gastro\u00f6sophagealen \u00dcbergangs sowie die gegen die PD-1\/PD-L1-Achse gerichteten Checkpoint-Inhibitoren, zu denen unter anderem Tislelizumab f\u00fcr das Plattenepithelkarzinom des \u00d6sophagus, Toripalimab f\u00fcr das Nasopharynxkarzinom, Sugemalimab f\u00fcr das NSCLC sowie das Retifanlimab f\u00fcr das Merkelzellkarzinom z\u00e4hlen.<\/jats:p>\n                  <jats:p>Die neuesten Therapiestrategien in der Behandlung des refrakt\u00e4ren multiplen Myeloms und B-Zell-Lymphoms liegen in der Anwendung bispezifischer Antik\u00f6rper. BCMA-CD3-bispezifische Wirkstoffe Elranatamab und Teclistamab sowie Talquetamab, ein GPRC5D-CD3-bispezifischer Antik\u00f6rper, wurden zur Behandlung des multiplen Myeloms zugelassen. Neu in der Behandlung des diffus gro\u00dfzelligen B-Zell-Lymphoms (DLBCL) sind die CD20-CD3-Antik\u00f6rper Glofitamab und Epcoritamab, die auch nach Therapieresistenz gegen chim\u00e4re Antigenrezeptor (CAR)-T-Zellen einen positiven prognostischen Effekt aufweisen.<\/jats:p>\n                  <jats:p>Die wichtigsten neuen Kombinationstherapien sind CD38-Antik\u00f6rper-basierte Immunchemotherapien als Erstlinienbehandlung des neu diagnostizierten multiplen Myeloms, Glofitamab+Gemcitabin und Oxaliplatin f\u00fcr die Therapie des rezidivierten\/refrakt\u00e4ren (r\/r) DLBCLs sowie die Kombination aus Checkpoint-Inhibitoren + Chemotherapie f\u00fcr die Erstlinientherapie der unresezierbaren oder metastasierten bili\u00e4ren\/urothelialen\/bronchialen\/nasopharyngealen und endometrialen Karzinome.<\/jats:p>\n                  <jats:p>Im Jahr 2024 erfolgte erstmals die Zulassung zweier T-Zell-basierter Therapien f\u00fcr solide Tumoren durch die FDA. Diese umfassen Lifileucel, eine Therapie mit tumorinfiltrierenden T-Lymphozyten (TILs) f\u00fcr das fortgeschrittene Melanom sowie Afamitresgene autoleucel, ein T-Zellrezeptor-modifiziertes T-Zell-Produkt zur Therapie des nicht resektablen Synovialsarkoms.<\/jats:p>\n                  <jats:p>Die Strategien zur Ausweitung von CAR-T-Zell-Therapien \u00fcber B-Zell-Malignome hinaus sind vielf\u00e4ltig. Modulierbare CAR-Plattformen, die Exploration von tumorspezifischen Zielstrukturen, duale Ans\u00e4tze sowie der Einsatz von zytokinsezernierenden CAR-T-Zellen gelten als zukunftsf\u00e4hig.<\/jats:p>","DOI":"10.1055\/a-2502-1305","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:58:13Z","timestamp":1761695893000},"page":"1335-1340","source":"Crossref","is-referenced-by-count":1,"title":["Aktuelle Fortschritte und neue Therapieoptionen in der Immunonkologie"],"prefix":"10.1055","volume":"150","author":[{"given":"Sebastian","family":"Kobold","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Klinische Pharmakologie, Klinikum der Universit\u00e4t M\u00fcnchen, Medizinische Klinik und Poliklinik IV,"},{"name":"Partner Standort M\u00fcnchen, eine Partnerschaft zwischen dem DKFZ Heidelberg und dem LMU Klinikum M\u00fcnchen, Deutsches Konsortium f\u00fcr Translationale Krebsforschung (DKTK), M\u00fcnchen"},{"name":"Deutsches Zentrum f\u00fcr Lungenforschung, M\u00fcnchen, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasmus","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Klinische Pharmakologie, Klinikum der Universit\u00e4t M\u00fcnchen, Medizinische Klinik und Poliklinik IV,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab Soravtansine in FRalpha-Positive, Platinum-Resistant Ovarian Cancer","volume":"389","author":"KN Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"K Shitara","year":"2023","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.21.01926","article-title":"Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study","volume":"40","author":"L Shen","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial","volume":"330","author":"HQ Mai","year":"2023","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","article-title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","volume":"23","author":"C Zhou","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.545","article-title":"545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201)","volume":"9","author":"G Grignani","year":"2021","journal-title":"J Immunother Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626616","article-title":"Bispecific Antibodies: From Research to Clinical Application","volume":"12","author":"J Ma","year":"2021","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"MJ Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"391","author":"T Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"P Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"JS Abramson","year":"2024","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma","volume":"389","author":"MS der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"T Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"RK Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142608","article-title":"The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity","volume":"16","author":"NTT Nguyen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144\u201301 study","volume":"10","author":"J Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"SP D\u02bcAngelo","year":"2024","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005054","article-title":"Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors","volume":"10","author":"S Stock","year":"2022","journal-title":"J Immunother Cancer"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1182\/blood.2023023210","article-title":"CD70 CAR T cells secreting an anti-CD33\/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML","volume":"145","author":"HJ Silva","year":"2025","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1038\/s41587-023-01684-0","article-title":"Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia","volume":"41","author":"A Gottschlich","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"11","key":"ref23","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Y Zhao","year":"2024","journal-title":"Nat Biotechnol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"D Steffin","year":"2025","journal-title":"Nature"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2502-1305.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:58:14Z","timestamp":1761695894000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2502-1305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":22,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,10,28]]},"published-print":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2502-1305","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"type":"print","value":"0012-0472"},{"type":"electronic","value":"1439-4413"}],"subject":[],"published":{"date-parts":[[2025,10,28]]}}}